InhaleRx Limited (IRX.AX)
AUD 0.04
(0.0%)
AUD 0.04
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.44 Million AUD | 23.9% |
| 2022 | -1.89 Million AUD | -70.69% |
| 2021 | -1.11 Million AUD | -9.87% |
| 2020 | -1.01 Million AUD | 55.5% |
| 2019 | -2.27 Million AUD | -21.22% |
| 2018 | -1.87 Million AUD | 10.51% |
| 2017 | -2.09 Million AUD | -501.39% |
| 2016 | -348.36 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -368.78 Thousand AUD | -1817.28% |
| 2024 Q2 | -368.78 Thousand AUD | 0.0% |
| 2023 Q2 | -1.42 Million AUD | -100.0% |
| 2023 Q1 | -712.01 Thousand AUD | 28.71% |
| 2023 FY | -1.44 Million AUD | 23.9% |
| 2023 Q4 | -19.23 Thousand AUD | -99.99% |
| 2023 Q3 | -9618.00 AUD | 99.32% |
| 2022 FY | -1.89 Million AUD | -70.69% |
| 2022 Q4 | -998.79 Thousand AUD | -100.0% |
| 2022 Q2 | -928.25 Thousand AUD | -100.0% |
| 2022 Q1 | -464.12 Thousand AUD | 16.24% |
| 2022 Q3 | -499.39 Thousand AUD | 46.2% |
| 2021 FY | -1.11 Million AUD | -9.87% |
| 2021 Q4 | -554.09 Thousand AUD | -100.0% |
| 2021 Q1 | -278.51 Thousand AUD | 62.32% |
| 2021 Q2 | -557.03 Thousand AUD | -100.0% |
| 2021 Q3 | -277.04 Thousand AUD | 50.26% |
| 2020 FY | -1.01 Million AUD | 55.5% |
| 2020 Q4 | -739.25 Thousand AUD | -100.0% |
| 2020 Q1 | -233.01 Thousand AUD | 82.68% |
| 2020 Q2 | -466.02 Thousand AUD | -100.0% |
| 2020 Q3 | -369.62 Thousand AUD | 20.69% |
| 2019 Q2 | -1.04 Million AUD | -100.0% |
| 2019 Q1 | -521.37 Thousand AUD | -71.18% |
| 2019 Q3 | -672.48 Thousand AUD | 35.51% |
| 2019 FY | -2.27 Million AUD | -21.22% |
| 2019 Q4 | -1.34 Million AUD | -100.0% |
| 2018 Q1 | -533.28 Thousand AUD | 23.91% |
| 2018 FY | -1.87 Million AUD | 10.51% |
| 2018 Q4 | -304.57 Thousand AUD | 0.0% |
| 2018 Q3 | -304.57 Thousand AUD | 42.89% |
| 2018 Q2 | -533.28 Thousand AUD | 0.0% |
| 2017 Q2 | -672.17 Thousand AUD | 0.0% |
| 2017 Q4 | -700.86 Thousand AUD | 0.0% |
| 2017 FY | -2.09 Million AUD | -501.39% |
| 2017 Q1 | -672.17 Thousand AUD | 0.0% |
| 2017 Q3 | -700.86 Thousand AUD | -4.27% |
| 2016 FY | -348.36 Thousand AUD | 0.0% |
| 2016 Q2 | -31.16 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 4DMedical Limited | -35.97 Million AUD | 95.989% |
| Adherium Limited | -10.22 Million AUD | 85.884% |
| Aroa Biosurgery Limited | -9.74 Million AUD | 85.195% |
| Atomo Diagnostics Limited | -6.84 Million AUD | 78.924% |
| Anteris Technologies Ltd | -67.33 Million AUD | 97.857% |
| Control Bionics Limited | -5.91 Million AUD | 75.595% |
| CardieX Limited | -6.76 Million AUD | 78.667% |
| Compumedics Limited | -338 Thousand AUD | -327.003% |
| Cochlear Limited | 356.8 Million AUD | 100.405% |
| CleanSpace Holdings Limited | -3.12 Million AUD | 53.847% |
| Cyclopharm Limited | -4.7 Million AUD | 69.297% |
| EMVision Medical Devices Ltd | -2.72 Million AUD | 47.125% |
| Nova Eye Medical Limited | -8.79 Million AUD | 83.581% |
| HeraMED Limited | -6.78 Million AUD | 78.724% |
| Imricor Medical Systems, Inc. | -22.62 Million AUD | 93.621% |
| ImpediMed Limited | -19.79 Million AUD | 92.707% |
| LBT Innovations Limited | -3.74 Million AUD | 61.41% |
| Micro-X Limited | -9.76 Million AUD | 85.22% |
| Neurotech International Limited | -5.06 Million AUD | 71.529% |
| OncoSil Medical Limited | -11.91 Million AUD | 87.886% |
| PolyNovo Limited | 5.26 Million AUD | 127.433% |
| Respiri Limited | -7.12 Million AUD | 79.756% |
| SomnoMed Limited | -12.24 Million AUD | 88.21% |
| Universal Biosensors, Inc. | -6.74 Million AUD | 78.591% |
| Uscom Limited | -2.07 Million AUD | 30.436% |
| Visioneering Technologies, Inc. | -5.06 Million AUD | 71.495% |